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It is well established that high expression of the antia-
poptotic Bcl-2 family proteins Bcl-2 and Bcl-xL can
signi¢cantly contribute to chemoresistance in a number
of human malignancies. Much less is known about the
role the more recently described Bcl-2 family member
Mcl-1 might play in tumor biology and resistance to
chemotherapy. Using an antisense strategy, we here ad-
dress this issue in melanoma, a paradigm of a treat-
ment-resistant malignancy. After in vitro proof of
principle supporting an antisense mechanism of action
with speci¢c reduction of Mcl-1 protein as a conse-
quence of nuclear uptake of the Mcl-1 antisense oligo-
nucleotides employed, antisense and universal control
oligonucleotides were administered systemically in
combination with dacarbazine in a human melanoma
SCID mouse xenotransplantation model. Dacarbazine,
available now for more than three decades, still remains
the most active single agent for treatment of advanced
melanoma. Mcl-1 antisense oligonucleotides speci¢cally
reduced target protein expression as well as the apopto-
tic threshold of melanoma xenotransplants. Combined
Mcl-1 antisense oligonucleotide plus dacarbazine treat-
ment resulted in enhanced tumor cell apoptosis and
led to a signi¢cantly reduced mean tumor weight
(mean 0.16 g, 95% con¢dence interval 0.08^0.26) com-
pared to the tumor weight in universal control oligonu-
cleotide plus dacarbazine treated animals (mean 0.35 g,
95% con¢dence interval 0.2^0.44) or saline plus dacarba-
zine treated animals (mean 0.39 g, 95% con¢dence in-
terval 0.25^0.53). We thus show that Mcl-1 is an
important factor contributing to the chemoresistance
of human melanoma in vivo. Antisense therapy against
the Mcl-1 gene product, possibly in combination with
antisense strategies targeting other antiapoptotic Bcl-2
family members, appears to be a rational and promis-
ing approach to help overcome treatment resistance of
malignant melanoma. Key words: antisense oligonucleotide/
apoptosis/chemoresistance/human melanoma/Mcl-1. J Invest
Dermatol 120:1081 ^1086, 2003
A
poptosis is important for the physiologic removal of
unwanted cells during development, for tissue
homeostasis, and in host defense mechanisms
(Thompson, 1995; Strasser et al, 1997; Vaux and
Korsmeyer, 1999). It provides an irreversible me-
chanism for the elimination of excess and damaged cells, and
induction of apoptosis is also the mechanism of action of various
chemotherapeutic agents (Lowe et al, 1993; 1994; Brown and
Wouters, 1999; Solary et al, 2001; Makin, 2002).
One key group of intracellular factors regulating apoptosis is
the Bcl-2 family of proteins. Bcl-2 was the founding member of
what is now a multigene family that consists of partially interact-
ing proteins that can be found in the evolution ladder from
mammals down to the nematodes (Hockenbery et al, 1990; Kors-
meyer, 1992; Cohen, 1993). A delicate balance between antiapop-
totic and proapoptotic Bcl-2 family members exists in each cell
and determines whether the cell survives or undergoes apoptosis.
Mcl-1 (myeloid cell leukemia-1) was ¢rst discovered as an early
induction gene during the di¡erentiation of a human myeloid
leukemia cell line (Kozopas et al, 1993). The Mcl-1 protein
contains structural motifs that characterize it as a member of the
Bcl-2 protein family. Like other Bcl-2 family members, the Mcl-
1 protein possesses Bcl-2 homology domains BH 1^3 (Akgul et al,
2000b; Bae et al, 2000). In contrast to Bcl-2 and Bcl-xL, Mcl-1
contains PEST (proline, glutamate, serine, and threonine) se-
quences (Rogers et al, 1986), which are commonly found in
proteins with a high turnover rate. Surprisingly, deletion of 104
amino acids (residues 79^183) that contain putative PEST se-
quences and other stability regulating motifs did not a¡ect pro-
tein stability (Akgul et al, 2000a). Moreover, the intracellular
distribution of Mcl-1 appears to be more widespread than Bcl-2
because, in addition to its predominant localization at the mito-
chondrial membranes, Mcl-1 is also distributed over a variety of
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nonmitochondrial compartments (Yang et al, 1995; Leuenroth
et al, 2000; Murphy et al, 2000). Mcl-1 has a short half-life
(1^3 h) (Rogers et al, 1986; Akgul et al, 2000b; Schubert and
Duronio, 2001) and is rapidly induced in a variety of cell types
(Kozopas et al, 1993; Akgul et al, 2000b).
The role of Mcl-1 expression in supporting cell survival has been
studied in various cell systems. Human neutrophils express neither
Bcl-2 nor Bcl-xL, but they do express Mcl-1. Upon shutdown
of Mcl-1 expression, this pro-survival gene product is
rapidly depleted, resulting in induction of apoptosis (Moulding
et al, 2001). Similarly, downregulation of Mcl-1 by antisense
oligonucleotides causes a rapid entry into apoptosis in di¡erentiat-
ing human myeloblastic leukemia cells (U937) (Moulding
et al, 2000). Overexpression of Mcl-1 in Chinese hamster ovary cells
(Reynolds et al, 1994; 1996) and murine myeloid progenitor cells
(FDC-P1) (Zhou et al, 1997), on the other hand, has been shown to
delay apoptosis induced by miscellaneous stimuli. Taken together,
Mcl-1 prolongs cell viability under various cytotoxic conditions
(etoposide, calcium ionophore, ultraviolet irradiation, growth factor
withdrawal) that cause apoptotic cell death, as has been also shown
in murine myleoid progenitor cells (Zhou et al, 1997).
The mechanisms through which Mcl-1 promotes cell survival,
however, are not clearly understood. Although reports on the in-
teraction of Apaf-1 and antiapoptotic Bcl-2 family members are
controversial, one possible mechanism is the inhibition of caspase
activation by retaining the adapter molecule Apaf-1 in an inactive
state (Moriishi et al, 1999; Conus et al, 2000). In HL-60 cells, an
increase of Mcl-1 has been associated with inhibition of apoptosis
by downregulating cell-damage-induced mitochondrial cyto-
chrome c release (Wang and Studzinski, 1997). Bcl-xL and Mcl-1
have in common the ability to heterodimerize with Bax, which
has been reported to translocate from cytosol to mitochondria
following exposure to apoptotic stresses and neutralize its cell
death-inducing activity (Akgul et al, 2000b; Pedersen et al, 2002).
Recently, it was shown that Mcl-1 is also widely expressed in
normal and malignant human melanocytic cell lines and in mel-
anoma metastases (Selzer et al, 1998). Increased Mcl-1 and Bcl-xL
levels were observed in thin primary melanomas as well as in me-
tastatic malignant melanomas but not in benign nevi, suggesting
that upregulation of these proteins represents an early event asso-
ciated with malignant transformation (Tang et al, 1998). Several
clinical studies have provided evidence for the hypothesis that
high level expression of antiapoptotic Bcl-2 family members,
such as Bcl-2, Bcl-xL, and Mcl-1, confers a clinically important
chemoresistant phenotype to cancer cells (Reed, 1995; 1998; Stras-
ser et al, 1997; Kaufmann et al, 1998). In human melanoma it was
recently reported that Bcl-2 (Jansen et al, 1998; 2000) expression is
linked to chemoresistance. Apoptosis and its regulation may play
an important pathogenic role in the development and chemore-
sistance of human melanoma (Serrone and Hersey, 1999).
Antisense oligonucleotides (ASO), chemically modi¢ed
stretches of single-stranded DNA, are pharmacologically potent
inhibitors of disease-related protein expression (Webb et al, 1997;
Jansen et al, 2000; Monia et al, 2000; Nicholson, 2000;Waters et al,
2000; Jansen and Zangemeister-Wittke, 2002). They are designed
to bind to their complementary mRNA sequence once they get
inside the cell, thereby inhibiting expression of the encoded pro-
tein (Myers and Dean, 2000).
Based on the available evidence, Mcl-1 seems to be a suitable
molecular target to enhance chemosensitivity in human melano-
ma. In this study we used Mcl-1 ASO to downregulate Mcl-1
protein expression in human melanoma cells in vitro and in vivo.
This downregulation chemosensitized human melanoma to sub-
sequent treatment with dacarbazine (DTIC) in a severe combined
immunode¢cient (SCID) mouse xenotransplantation model.
MATERIALS AND METHODS
Cell lines and culture The human melanoma cell line 518A2 was a kind
gift of Peter Schrier, University of Leiden (The Netherlands), which has
been described recently (Jansen et al, 1998). The human melanoma cell line
Mel Juso (Lehmann et al, 1989) was kindly provided by Dr. Judith Johnson
(University of Munich, Germany). All cell lines were maintained in
Dulbecco’s modi¢ed Eagle’s culture medium (DMEM) supplemented
with 10% fetal bovine serum (Gibco, Paisley, U.K.) and an antibiotic
mixture containing 100 units per ml penicillin, 100 mg per ml
streptomycin, and 0.25 mg per ml amphotericin B (all Gibco) in a fully
humidi¢ed 5% CO2, 95% ambient air atmosphere at 371C.
Oligonucleotides and transfection 20 -O-Methoxyethyl/20 -deoxy-
nucleotide chimeric phosphorothioate antisense oligonucleotides were
kindly provided by ISIS Pharmaceuticals (Carlsbad, CA). The sequence of
Mcl-1 antisense oligonucleotide (ISIS 20408) is 50 -TTGGCTTTGTG
TCCTTGGCG-30. A universal control oligonucleotide pool (ISIS 29848)
was used, which is synthesized as a mixture of A (adenine), G (guanine),
T (thymine), and C (cytosine) bases so that the resulting preparation
contains an equimolar mixture of all possible oligonucleotides. The
oligonucleotide chemistry of ISIS 29848 is identical to that of ISIS 20408.
For cellular uptake studies Mcl-1 ASO is £uorescein-labeled with a 50 -
oligonucleotide £uorescein labeling kit (Amersham, Buckinghamshire,
U.K.) according to the manufacturer’s instructions.
For transfection, 300,000 cells were seeded in a 75 cm2 plate 24 h prior to
the oligonucleotide treatment. Oligonucleotides were complexed with
lipofectin (Gibco) in antibiotic-free medium without serum as described
by the supplier. Subsequently, cells were incubated for 4 h with 250 nM
complexed oligonucleotides (10 mg per ml lipofectin) in antibiotic-free
medium without serum. After washing with DMEM, cells were further
cultured in complete medium containing serum. Alternatively, cells
were incubated with oligonucleotides (1 mM) for 24 h in medium
supplemented with 10% fetal bovine serum.
Oligonucleotide uptake Following incubation with £uorescein-labeled
oligonucleotides with and without uptake-enhancing lipids cells were
¢xed with paraformaldehyde (Sigma, St. Louis, MO) (4% in phosphate-
bu¡ered saline). Slides were evaluated under an Axioplan 2 (Zeiss,Vienna,
Austria) £uorescence microscope equipped with a Zeiss Axiocam using
Axiovision 3.0 (Zeiss) software.
Western blot analysis Cell extracts were prepared in lysis bu¡er
containing 0.14 M NaCl, 0.4 M triethanolamine, 0.2% Na deoxycholate,
and 0.5% Nonidet P-40, supplemented with 1 mM phenylmethylsulfonyl
£uoride, 4.0 mg per ml aprotinin, and 4.0 mg per ml leupeptin. The amount
of soluble proteins was quanti¢ed by means of a modi¢ed Bradford
analysis (Bio-Rad, Richmond, CA). Total lysates (15 mg per lane) were
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis,
blotted onto polyvinylidene £uoride membranes (Millipore, Bedford,
MA), and probed with anti-Mcl-1 (Santa Cruz Biotechnology, Santa
Cruz, CA) or anti-b-tubulin (Sigma) antibody. Alkaline-phosphatase-
conjugated goat antimouse and goat antirabbit immunoglobulins (Tropix,
Bedford, MA) were used for secondary incubations. Reactive bands were
visualized by chemiluminescence using CSPDs as substrate (Tropix).
Protein expression levels were quanti¢ed by densitometry of
autoradiograms with an Ultrascan XL densitometer (Pharmacia, Uppsala,
Sweden).
Evaluation of oligonucleotide e¡ects in vivo Pathogen-free female
C.B.-17 scid/scid (SCID) mice (4^6 wk, Harlan Winkelmann, Borchen,
Germany) were randomly assigned to experimental groups of six animals
each. SCID mice were injected subcutaneously with 2107 518A2 human
melanoma cells into the lower left £ank. Seven days after injection, animals
had developed melanomas of similar size (nodules of about 5 mm in
diameter) and treatment was initiated. Animals were anesthetized and
miniosmotic pumps (Alzet 2002, Alzet, Palo Alto, CA) pre¢lled with
saline, antisense, or universal control oligonucleotides were inserted
subcutaneously into a paraspinal pocket. Implanted pumps released their
contents by continuous infusion at a rate of 20 mg per kg per d over a
period of 2 wk. Mice were treated with DTIC (80 mg per kg per d)
administered intravenously for 5 d (days 12^16). During the experiments,
tumor weight was assessed twice a week by caliper measurement as
previously described (Boehm et al, 1997). On day 21 all animals were
sacri¢ced, tumors were weighed, and tumor xenotransplants were ¢xed in
formalin for immunohistochimestry and terminal deoxynucleotidyl
transferase mediated dUTP nick end labeling (TUNEL) analysis.
Apoptosis assay and immunohistochemistry Histology of human
melanoma xenotransplants was evaluated by hematoxylin and eosin
staining. The histochemical detection of apoptosis in formalin-¢xed
sections was performed by TUNEL using £uorescein-dUTP (Boehringer
Mannheim, Germany). Tissue sections were counterstained using DAPI
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(40,6 -diamidine-20 -phenylindole dihydrochloride, Roche Diagnostics,
Vienna, Austria).
The expression pattern of Mcl-1 in vivo was evaluated by
immunohistochemistry with an anti-Mcl-1 antibody (1:50, Santa Cruz
Biotechnology) and a DAKO LSAB 2 System using diaminobenzidine as
chromogen.
Statistical analysis Statistical signi¢cance of di¡erences in tumor
weight among treatment groups was calculated by using one-way
ANOVA and the Sche¡e test for post hoc testing (SPSS 10.0.7, SPSS,
Chicago, IL). p-values less than 0.05 were considered to be of statistical
signi¢cance.
RESULTS
Uptake of Mcl-1 antisense oligonucleotides in human
melanoma cells in vitro To assess the e⁄ciency of
oligonucleotide uptake, 518A2 human melanoma cells were
incubated with 250 nM or 1 mM £uorescein-labeled Mcl-1 ASO
in the presence or absence of uptake-enhancing lipids,
respectively. Twenty-four hours later cells were ¢xed with
paraformaldehyde and evaluated by £uorescence microscopy.
Fluorescein-labeled oligonucleotides were found to be localized
to the nucleus but also to the cytosol as well as to vesicular
compartments (Fig 1). These ¢ndings were also demonstrated
for another human melanoma cell line (Mel JUSO; data not
shown).
Reduction of Mcl-1 protein by Mcl-1 antisense
oligonucleotides in human melanoma cells in vitro The
two melanoma cell lines used in this work were shown to
express the antiapoptotic protein Mcl-1 (Fig 2). Using Mcl-1
ASO at nanomolar concentrations in the presence of the uptake
enhancer lipofectin, we observed a pronounced reduction in Mcl-
1 levels in our cell lines in vitro (Fig 2). Normalization to b-
tubulin demonstrated that ASO treatment caused a signi¢cant
reduction of Mcl-1 protein levels compared to saline-control-
treated cell lines. In 518A2 cells, ASO treatment reduced Mcl-1
levels by 84% [95% con¢dence interval (CI) 79.03^88.97],
whereas in Mel Juso cells a reduction of 83% (CI 95% 74.00^
93.68) was detected (data are given as the range of three
independent experiments and are expressed relative to
lipofectin-treated control cells). In contrast, universal control
treatment decreased Mcl-1 levels by 5% (95% CI 4.70^15.37) in
518A2 cells and 11% (95% CI 3.35^19.32) in Mel Juso cells.
Similarly, e¡ects were also observed at a higher oligonucleotide
concentration in the absence of uptake-enhancing lipids (data
not shown). Treatment of melanoma cells with Mcl-1 ASO did
not change Bcl-2 or Bcl-xL protein levels (data not shown).
Immunohistochemical analysis of Mcl-1 protein levels in
518A2 human melanomas in vivo To test whether Mcl-1
ASO is capable of downregulating Mcl-1 expression in vivo,
Mcl-1 ASO, universal control oligonucleotides, or saline as a
vehicle control were administered to SCID mice bearing sub-
cutaneously implanted 518A2 tumors. After 14 d of treatment
the expression pattern of Mcl-1 was evaluated by immuno-
histochemistry (Fig 3). Mcl-1-speci¢c staining was found in all
specimens evaluated; however, levels were markedly reduced in
Mcl-1 ASO treated tumors compared to mice that received
either saline or control oligonucleotides.
Mcl-1 ASO treatment chemosensitizes human melanoma
in vivo Based on these ¢ndings we next tested whether
reduction of Mcl-1 expression has the potential to enhance the
chemosensitivity of melanoma xenotransplants. Tumor size
measurements with a caliper during the course of the
experiment already indicated that tumor growth is reduced in
mice treated with Mcl-1 ASO/DTIC compared to mice treated
with either universal control oligonucleotide-DTIC or saline/
DTIC (Fig 4a). This observation was con¢rmed by assessing the
tumor weight at the end of the experiment (Fig 4b). The
Figure1. In vitro oligonucleotide uptake by human melanoma
cells. 518A2 cells were incubated with £uorescein-labeled Mcl-1 ASO
(a) 250 nM, in the presence of uptake-enhancing lipids (lipofectin); (b) 1
mM, without uptake-enhancing lipids. Twenty-four hours later, cells
were ¢xed with paraformaldehyde and evaluated under a £uorescence
microscope. Original magni¢cation: 400 .
Figure 2. In vitro Mcl-1 downregulation in human melanoma cells.
518A2 and Mel Juso cells were incubated for 4 h with the indicated oligo-
nucleotides or vehicle control (AS, antisense; UC, universal control, SAL,
saline control) in the presence of lipofectin. Twenty-four hours later, pro-
tein was extracted and analyzed for Mcl-1 and b-tubulin expression by
Western blotting. Representative data from one of three independent
experiments are shown.
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combination of Mcl-1 ASO and DTIC resulted in a signi¢cantly
lower mean tumor weight (mean 0.16 g, 95% CI 0.08^0.26)
compared to saline plus DTIC (mean 0.39 g, 95% CI 0.25^0.53)
or universal control oligonucleotides plus DTIC (mean 0.35 g,
95% CI 0.27^0.44) (Fig 4b). DTIC alone exerted an
antineoplastic response without eradicating the tumors and
reduced the mean tumor weight compared with that of
untreated animals by approximately two-thirds. Assessing the
in£uence of oligonucleotide monotreatment in an independent
pilot experiment, no signi¢cant di¡erences were found in the
mean tumor weight between mice treated with ASO alone
(mean 1.85 g, 95% CI 1.53^2.17) or universal control
oligonucleotides (mean 1.85 g, CI 1.35^2.35) compared to those
treated with saline (mean 2.00 g, 95% CI 1.27^2.90).
Detection of apoptosis in human melanomas grown in scid
mice by TUNEL To investigate whether this chemosensi-
tization e¡ect by Mcl-1 ASO was linked to a higher rate of
apoptotic cell death in tumor xenografts, tumors were examined
for apoptotic cell death byTUNEL staining (Fig 4b). Mcl-1ASO
plus DTIC treatment increased the number of apoptotic cells
approximately 2-fold (7% apoptotic cells) within 518A2 tumors
compared to the saline plus DTIC or the universal control plus
DTIC control group (2% and 3% apoptotic cells, respectively).
DISCUSSION
The expansion of a tumor is directly related to the di¡erence in
the rates of proliferation and cell death (apoptotic and necrotic
Figure 3. Downregulation of Mcl-1 expression in human melano-
mas grown in SCID mice. Immunohistochemical detection of Mcl-1
in tumor xenotransplants of mice with established 518A2 tumors were trea-
ted for 14 d with the indicated oligonucleotide (a, SAL; b, UC; c, AS) de-
livered by miniosmotic pumps.
Figure 4. Mcl-1 ASO chemosensitizes human melanoma in vivo.
SCID mice with established 518A2 tumors received a 14 d infusion by
miniosmotic pumps of Mcl-1 ASO (AS), universal control oligonucleotide
(UC), or saline (n¼ 6 animals per group). In addition, animals received
DTIC treatment on days 12^16. (a) During the course of the experiment
tumor size was assessed by caliper measurement and is given in mL as
mean7SD. (b) At the end of the experiment (day 21) tumors were resected
and weighed. Tumor weight is given in mg as mean7SD. Furthermore,
melanoma xenografts were analyzed byTUNEL assay (apoptotic cells ap-
pear green) and counterstained with DAPI. Representative photographs of
tumors are shown. Original magni¢cation: 200 .
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cell death). Apoptosis plays an indispensable role in the mainte-
nance of homeostasis within tissue. Moreover, impaired apoptosis
may promote metastasis by enabling tumor cells to survive in the
circulation and to grow at distant sites even in the absence of an
otherwise required ¢ne-tuned growth factor milieu.
Apoptosis is a highly conserved cellular process activated in re-
sponse to a variety of stimuli, which culminates in the activation
of nucleases and cysteine aspartic acid speci¢c proteases (caspases)
responsible of degradation of cellular proteins that ultimately lead
to a decay of a¡ected cells (Reed, 1998). The Bcl-2 family of pro-
teins is of special relevance, as its members act at a checkpoint
upstream of e¡ector caspases and other apoptosis regulators
(Chao and Korsmeyer, 1998).
Given the widespread expression of the antiapoptotic Bcl-2 fa-
mily member Mcl-1 in human melanoma (Selzer et al, 1998;Tang
et al, 1998) and experimental evidence from other systems, we
hypothesized that Mcl-1 may be one key factor in£uencing the
chemosensitivity of this malignancy. In contrast to Bcl-2 (Jansen
et al, 1998; 2000) and Bcl-xL (Heere-Ress et al, 2002) there is no
direct experimental information regarding the role that Mcl-1
might play in the control of apoptosis and/or chemoresistance of
human melanoma.
The aim of this study was to address this issue and to restore
the apoptosis signaling pathway in human melanoma by down-
regulation of Mcl-1 protein expression employing ASO. ASO are
useful tools for biologic research and hold great promise as a new
class of therapeutic agents. They provide an interesting approach
for the development of target-selective drugs, which can be mod-
i¢ed and optimized with relative ease. In this study, a Mcl-1 ASO
previously shown to be capable of downregulating Mcl-1 expres-
sion in endothelial cells were used (Bannerman et al, 2001). In vitro
experiments demonstrated a strong and speci¢c downregulation
of the Mcl-1 target protein in human melanoma cells. The obser-
vation that expression of Bcl-2 and Bcl-xL, two other antiapop-
totic members of the Bcl-2 family with homology to the Mcl-1
protein (Kozopas et al, 1993; Johnson, 1999), was not altered by
Mcl-1 ASO treatment (data not shown) further supports a speci-
¢c antisense mechanism of action of the Mcl-1 ASO used.
Furthermore, in a recent report an Mcl-1 ASO with the identical
sequence was found to cause a pronounced Mcl-1 downregula-
tion in endothelial cells, whereas a control oligonucleotide that
contained four mismatches was without any e¡ect on Mcl-1
expression levels (Bannerman et al, 2001). Notably, no reciprocal
upregulation of Bcl-2 or Bcl-xLwas observed in our studies.This
phenomenon had been reported as a compensatory mechanism
after downregulation of other Bcl-2 family members in certain
malignancies (Hockenbery et al, 1990; Chao and Korsmeyer, 1998).
By employing immunohistochemical analysis, we also
demonstrated a strong Mcl-1 downregulation in 518A2 human
melanoma grown in SCID mice following systemic administra-
tion of Mcl-1 ASO. Assessing antitumor response, we observed a
clear chemosensitizing e¡ect of Mcl-1 ASO to DTIC for human
melanoma. In contrast to previous reports on Bcl-2 antisense
strategies (Jansen et al, 1998; Wacheck et al, 2001), single agent
ASO treatment did not signi¢cantly alter tumor growth
compared to untreated mice. As previously observed (Jansen
et al, 1998) DTIC exerted an antineoplastic response; however,
Mcl-1 ASO plus DTIC further reduced tumor weight by
approximately 60%.
Several clinical correlative studies have provided support for
the hypothesis that high Bcl-2, Bcl-xL, and Mcl-1 expression
confers a clinically relevant chemoresistant phenotype to cancer
cells (Reed, 1995; 1998; Strasser et al, 1997).
The data presented here clearly provide ¢rst direct evidence
that Mcl-1 contributes to chemoresistance in human malignant
melanoma that is independent of Bcl-2 and Bcl-xL.We further
show for the ¢rst time that Mcl-1 downregulation by ASO has
the potential to enhance chemosensitivity in melanoma in vivo.
Although the exact mechanism remains elusive, Mcl-1 may exert
its antiapoptotic function by heterodimerization with Bax, there-
by neutralizing its death inducing activity (Murphy et al, 2000;
Pedersen et al, 2002), or by interacting with Apaf-1. Reports on
the interaction of antiapoptotic Bcl-2 family members with this
adapter molecule remain somewhat controversial, however
(Moriishi et al, 1999; Conus et al, 2000).
Previously, our group reported a chemosensitizing e¡ect of
Bcl-2 ASO ^ also without e¡ects on Bcl-xL levels ^ in human
melanoma both preclinically and in a recently completed phase
I/II trial (Jansen et al, 1998; 2000). Preclinical antisense strategies
using monospeci¢c or even bispeci¢c ASO against Bcl-2 and/or
Bcl-xL have shown promise as treatment options for malignant
melanoma (Heere-Ress et al, 2002; Olie et al, 2002). The balance
between antiapoptotic and pro-apoptotic Bcl-2 family members
determines the threshold of susceptibility to chemotherapy.
Therefore, it is reasonable to speculate that antisense strategies
may prove even more promising if ultimately more than one of
the antiapoptotic family members that exhibit a certain degree of
redundancy in inhibiting apoptosis is targeted in combination
with chemotherapy. As our group previously reported a chemo-
sensitizing e¡ect of Bcl-2 ASO in human melanoma (Jansen et al,
1998; 2000), a combination of ASO targeted against Bcl-2 as well
as against Mcl-1 and/or Bcl-xL may prove even more promising.
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